腹膜癌腫症(PC)の疫学予測(~2028)

◆英語タイトル:Peritoneal Carcinomatosis (PC) Epidemiology Forecast to 2028
◆商品コード:DATA00109002
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2019年12月
◆ページ数:70
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD3,250 ⇒換算¥370,500見積依頼/購入/質問フォーム
Global Site License(法人閲覧用)USD9,750 ⇒換算¥1,111,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
DelveInsight社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Peritoneal Carcinomatosis (PC) Epidemiology Forecast to 2028
DelveInsight’s ‘Peritoneal Carcinomatosis (PC)- Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Peritoneal Carcinomatosis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain and the United Kingdom)
• Japan

Study Period: 2017-2028

Peritoneal Carcinomatosis Disease Understanding

Peritoneal Carcinomatosis (PC) generally refers to the metastatic involvement of peritoneum. It is a rare type of cancer that can develop when gastrointestinal or gynecologic cancers spread. It can cause tumors to grow in the peritoneum. Classically, it has been a condition of fatal evolution that leads to the death of the patient by cancer evolution in a period rarely exceeding 6 months. It is intraperitoneal dissemination of any form of cancer that does not originate from the peritoneum itself.

Peritoneal Carcinomatosis Epidemiology

The Peritoneal Carcinomatosis (PC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Peritoneal Carcinomatosis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Peritoneal Carcinomatosis Epidemiology Segmentation

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Incidence of PC in Advanced Stage Cancers, Incidence of PC in Site Specific Cancers, Total Incidence of PC in Recurrent Cases, Incidence of PC by site-specific Recurrent Cases) scenario of Peritoneal Carcinomatosis (PC) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of incident cases of Peritoneal Carcinomatosis (PC) in 7 MM was found to be 91,416 in the year 2017.

Report Scope

• The report covers detailed overview of Peritoneal Carcinomatosis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The report provides the insight about the historical and forecasted patient pool of Peritoneal Carcinomatosis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
• The Report assesses the disease risk and burden and highlights the unmet needs of the disease
• The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
• The report provides the segmentation of the disease epidemiology by Total Incidence of PC in Advanced Stage Cancers, Incidence of PC in Site Specific Cancers, Total Incidence of PC in Recurrent Cases, Incidence of PC by site-specific Recurrent Cases in 7MM

Key strengths

• 10 Years Forecast
• 7MM Coverage
• Epidemiology Segmentation
• Key Cross Competition
• Market Size by Therapies
• Drugs Uptake

Key assessments

• Pipeline Product Profiles
• Key Products and Key Players
• Market Drivers and Barriers

Note: We understand the needs of the rapidly changing market and DelveInsight’s is helping the clients by providing them with the most up to date Report. It usually takes 24 Hours.

【レポートの目次】

1. Key Insights
2. Peritoneal Carcinomatosis Market Overview at a Glance
2.1. Market Share (%) Distribution of Peritoneal Carcinomatosis Market in 2017
2.2. Market Share (%) Distribution of Peritoneal Carcinomatosis Market in 2028
3. Disease Background and Overview
3.1. Introduction
3.2. Natural History of Peritoneal Carcinomatosis
3.3. Classification of Causes of Peritoneal disease
3.4. Symptoms of Peritoneal Carcinomatosis
3.5. Pathophysiology of Peritoneal Carcinomatosis
3.6. Scoring System
3.7. Diagnosis
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. 7MM Total Patient Population of Peritoneal Carcinomatosis
4.3. KOL Views
5. Epidemiology – Assumptions and Rationale
6. Country Wise-Epidemiology of PC
6.1. United States
6.1.1. Assumptions and Rationale
6.1.2. Total Incidence of PC in Advanced Stage Cancers
6.1.3. Incidence of PC in Site Specific Cancers
6.1.4. Total Incidence of PC in Recurrent Cases
6.1.5. Incidence of PC by site-specific Recurrent Cases
6.2. EU5 Countries
6.2.1. Assumptions and Rationale
6.3. Germany
6.3.1. Total Incidence of PC in Advanced Stage Cancers
6.3.2. Incidence of PC in Site Specific Cancers
6.3.3. Total Incidence of PC in Recurrent Cases
6.3.4. Incidence of PC by site-specific Recurrent Cases
6.4. France
6.4.1. Total Incidence of PC in Advanced Stage Cancers
6.4.2. Incidence of PC in Site Specific Cancers
6.4.3. Total Incidence of PC in Recurrent Cases
6.4.4. Incidence of PC by site-specific Recurrent Cases
6.5. Italy
6.5.1. Total Incidence of PC in Advanced Stage Cancers
6.5.2. Incidence of PC in Site Specific Cancers
6.5.3. Total Incidence of PC in Recurrent Cases
6.5.4. Incidence of PC by site-specific Recurrent Cases
6.6. Spain
6.6.1. Total Incidence of PC in Advanced Stage Cancers
6.6.2. Incidence of PC in Site Specific Cancers
6.6.3. Total Incidence of PC in Recurrent Cases
6.6.4. Incidence of PC by site-specific Recurrent Cases
6.7. United Kingdom
6.7.1. Total Incidence of PC in Advanced Stage Cancers
6.7.2. Incidence of PC in Site Specific Cancers
6.7.3. Total Incidence of PC in Recurrent Cases
6.7.4. Incidence of PC by site-specific Recurrent Cases
6.8. Japan
6.8.1. Assumptions and Rationale
6.8.2. Total Incidence of PC in Advanced Stage Cancers
6.8.3. Incidence of PC in Site Specific Cancers
6.8.4. Total Incidence of PC in Recurrent Cases
6.8.5. Incidence of PC by site-specific Recurrent Cases
7. Treatment
8. Unmet Needs
9. Appendix
9.1. Report Methodology
10. DelveInsight Capabilities
11. Disclaimer
12. About DelveInsight
Table 1: Key morphological features identified in metastatic carcinoma in ascites
Table 2: Comparison of imaging techniques
Table 3: Total Population of Peritoneal Carcinomatosis in the 7MM (2017-2028)
Table 4: Total Incidence of PC in Advanced Stage Cancers in the US (2017-2028)
Table 5: Incidence of PC in Site Specific Cancers in the US (2017-2028)
Table 6: Total Incidence of PC in Recurrent Cases in the US (2017-2028)
Table 7: Incidence of PC by site-specific Recurrent Cases in the US (2017-2028)
Table 8: Total Incidence of PC in Advanced Stage Cancers in Germany (2017-2028)
Table 9: Incidence of PC in Site Specific Cancers in Germany (2017-2028)
Table 10: Total Incidence of PC in Recurrent Cases in Germany (2017-2028)
Table 11: Incidence of PC by site-specific Recurrent Cases in Germany (2017-2028)
Table 12: Total Incidence of PC in Advanced Stage Cancers in France (2017-2028)
Table 13: Incidence of PC in Site Specific Cancers in France (2017-2028)
Table 14: Total Incidence of PC in Recurrent Cases in France (2017-2028)
Table 15: Incidence of PC by site-specific Recurrent Cases in France (2017-2028)
Table 16: Total Incidence of PC in Advanced Stage Cancers in Italy (2017-2028)
Table 17: Incidence of PC in Site Specific Cancers in Italy (2017-2028)
Table 18: Total Incidence of PC in Recurrent Cases in Italy (2017-2028)
Table 19: Incidence of PC by site-specific Recurrent Cases in Italy (2017-2028)
Table 20: Total Incidence of PC in Advanced Stage Cancers in Spain (2017-2028)
Table 21: Incidence of PC in Site Specific Cancers in Spain (2017-2028)
Table 22: Total Incidence of PC in Recurrent Cases in Spain (2017-2028)
Table 23: Incidence of PC by site-specific Recurrent Cases in Spain (2017-2028)
Table 24: Total Incidence of PC in Advanced Stage Cancers in the UK (2017-2028)
Table 25: Incidence of PC in Site Specific Cancers in the UK (2017-2028)
Table 26: Total Incidence of PC in Recurrent Cases in the UK (2017-2028)
Table 27: Incidence of PC by site-specific Recurrent Cases in the UK (2017-2028)
Table 28: Total Incidence of PC in Advanced Stage Cancers in Japan (2017-2028)
Table 29: Incidence of PC in Site Specific Cancers in Japan (2017-2028)
Table 30: Total Incidence of PC in Recurrent Cases in Japan (2017-2028)
Table 31: Incidence of PC by site-specific Recurrent Cases in Japan (2017-2028)
Figure 1: Anatomy of a Peritoneum
Figure 2: Types of Carcinomatosis
Figure 3: Ascites
Figure 4: Classification based on Primary and Secondary Tumors:
Figure 5: Classification based on Neoplastic and Non-neoplastic Conditions:
Figure 6: Tumor Entrapment Hypothesis in Gastric Cancer:
Figure 7: Symptoms of PC
Figure 8: The Peritoneal Metastatic Cascade:
Figure 9: The Peritoneal Cancer Index (PCI):
Figure 10: Diagnostic decision tree for identifying primary cancer which has metastatized to peritoneum
Figure 11: Total Diagnosed Patient Population of Peritoneal Carcinomatosiss in the 7MM (2017-2028)
Figure 12: Total Incidence of PC in Advanced Stage Cancers in the US (2017-2028)
Figure 13: Incidence of PC in Site Specific Cancers in the US (2017-2028)
Figure 14: Total Incidence of PC in Recurrent Cases in the US (2017-2028)
Figure 15: Incidence of PC by site-specific Recurrent Case sin the US (2017-2028)
Figure 16: Total Incidence of PC in Advanced Stage Cancers in Germany (2017-2028)
Figure 17: Incidence of PC in Site Specific Cancers in Germany (2017-2028)
Figure 18: Total Incidence of PC in Recurrent Cases in Germany (2017-2028)
Figure 19: Incidence of PC by site-specific Recurrent Cases in Germany (2017-2028)
Figure 20: Total Incidence of PC in Advanced Stage Cancers in France (2017-2028)
Figure 21: Incidence of PC in Site Specific Cancers in France (2017-2028)
Figure 22: Total Incidence of PC in Recurrent Cases in France (2017-2028)
Figure 23: Incidence of PC by site-specific Recurrent Cases in France (2017-2028)
Figure 24: Total Incidence of PC in Advanced Stage Cancers in Italy (2017-2028)
Figure 25: Incidence of PC in Site Specific Cancers in Italy (2017-2028)
Figure 26: Total Incidence of PC in Recurrent Cases in Italy (2017-2028)
Figure 27: Incidence of PC by site-specific Recurrent Cases in Italy (2017-2028)
Figure 28: Total Incidence of PC in Advanced Stage Cancers in Spain (2017-2028)
Figure 29: Incidence of PC in Site Specific Cancers in Spain (2017-2028)
Figure 30: Total Incidence of PC in Recurrent Cases in Spain (2017-2028)
Figure 31: Incidence of PC by site-specific Recurrent Case sin Spain (2017-2028)
Figure 32: Total Incidence of PC in Advanced Stage Cancers in the UK (2017-2028)
Figure 33: Incidence of PC in Site Specific Cancers in the UK (2017-2028)
Figure 34: Total Incidence of PC in Recurrent Cases in the UK (2017-2028)
Figure 35: Incidence of PC by site-specific Recurrent Cases in the UK (2017-2028)
Figure 36: Total Incidence of PC in Advanced Stage Cancers in Japan (2017-2028)
Figure 37: Incidence of PC in Site Specific Cancers in Japan (2017-2028)
Figure 38: Total Incidence of PC in Recurrent Cases in Japan (2017-2028)
Figure 39: Incidence of PC by site-specific Recurrent Cases in Japan (2017-2028)
Figure 40: HIPEC Treatment
Figure 41: Treatment algorithm
Figure 42: Unmet Needs



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[腹膜癌腫症(PC)の疫学予測(~2028)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆